You can now listen to Fox News articles! The U. S. Food and Drug Administration (FDA) has given its approval to the first artificial intelligence (AI) tool designed to predict breast cancer risk. This approval was announced by Clairity, a digital health technology company, which developed Clairity Breast—a cutting-edge, image-based prognostic platform that predicts a five-year breast cancer risk from a routine screening mammogram. In a press release, Clairity revealed plans to deploy the AI platform across health systems through 2025. AI DETECTS OVARIAN CANCER MORE ACCURATELY THAN HUMAN EXPERTS IN NEW STUDY According to Clairity, most breast cancer risk assessment models largely depend on factors like age and family history. However, health agencies report that about 85% of breast cancer cases occur in women without a family history of the disease, likely due to genetic mutations arising from aging. Moreover, traditional risk models have been primarily based on data from European Caucasian women, which Clairity notes has not been "generalized well" for diverse populations. The AI tool examines subtle features in mammogram images that are linked to breast cancer risk, then produces a "validated five-year risk score" that is communicated to healthcare providers, the company explained. AI DETECTS WOMAN’S BREAST CANCER AFTER IT WAS MISSED IN ROUTINE SCREENING: 'DEEPLY GRATEFUL' Dr. Connie Lehman, founder of Clairity and breast imaging specialist at Mass General Brigham, emphasized mammograms’ vital role in early cancer detection. "Advances in AI and computer vision can now reveal hidden signs in mammograms—undetectable to the human eye—that help forecast future risk, " she stated in a press release. "By providing validated, equitable risk assessments, we can broaden access to life-saving early detection and prevention for women everywhere. " CLICK HERE TO GET THE FOX NEWS APP Dr. Robert A. Smith, senior vice president for early cancer detection science at the American Cancer Society, remarked that personalized, risk-based screening is "critical to improving breast cancer outcomes, " with AI tools offering the best chance to realize that goal. "This is the wave of the future.

AI will be part of the process, but it will not replace humans. " Larry Norton, founding scientific director of the Breast Cancer Research Foundation, called Clairity’s FDA approval a milestone for expanding access to AI-driven cancer risk prediction. "Breast cancer cases are rising, especially among younger women, yet many risk models often fail to identify those who will develop the disease, " he said. "Now we can ensure that more women receive the right care at the right time. " Despite "decades of progress, " more than 2. 3 million women worldwide are diagnosed with breast cancer annually, including over 370, 000 in the U. S. , according to the Breast Cancer Research Foundation. The incidence has notably increased among women under 50 years of age. CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER During a recent appearance on "America’s Newsroom, " Fox News senior medical analyst Dr. Marc Siegel called Clairity’s innovation "profound. " "Radiologists sometimes detect uncertain areas on mammograms and must monitor them over time, " he said. "AI significantly enhances the focus and predictive power, as demonstrated in numerous studies. " Siegel noted that radiologists nationwide generally support using AI for cancer detection, particularly in regions with limited healthcare access. "In areas relying on radiologists without specialized training, this technology is even more crucial, " he added. "This is the wave of the future. AI will be part of the equation, but it will not take over. " For more Health articles, visit www. foxnews. com/health